Progress in the treatment of blood hypercoagulability in patients with non-small cell lung cancer

DOI: 10.12201/bmr.202506.00015

•  

  Abstract: Based on clinical data, it is found that non-small cell lung cancer patients generally have hypercoagulable state of blood, and hypercoagulable state of blood promotes disease progression and causes complications including venous thromboembolism, which is an important factor leading to the death of patients. According to Western medicine, the causes of hypercoagulability are complex and varied, including vascular endothelial damage, tissue factor abnormality, inhibition of anticoagulant and fibrinolytic systems, and so on. Chinese medicine believes that there are stasis due to deficiency, stasis due to toxicity, stasis due to seven emotions, and stasis due to blood outflow. The article provides a brief review of the occurrence mechanism of hypercoagulability in non-small cell lung cancer patients, the pathogenesis of Chinese medicine, and the progress of Chinese and Western medicine treatment, so as to provide a certain reference for the treatment of non-small cell lung cancer patients with hypercoagulability.

  Key words: Non-small cell lung cancer; hypercoagulable state of blood; treatment; extravasated blood

  Submit time: 7 June 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• Zhang Xinzhong. Research progress on folate receptor positive circulating tumor cells and the occurrence and development of non-small cell lung cancer. 2025. doi: 10.12201/bmr.202506.00024

  付思思. Construction and validation of Nomogram analysis model for nausea and vomiting after lobectomy in non-small cell lung cancer patients. 2025. doi: 10.12201/bmr.202507.00001

  李娜, Luo bingqing. Clinical observation of microwave ablation combined with chemotherapy and PD-1 inhibitor for non-small cell lung cancer.. 2025. doi: 10.12201/bmr.202504.00054

  Clinical research progress of PD-1/PD-L1 inhibitor induction therapy in unresectable stage III non-small-cell lung cancer. 2025. doi: 10.12201/bmr.202501.00025

  Research progress of red blood cell storage lesion. 2025. doi: 10.12201/bmr.202502.00021

  Tang jianjun, zhang weiyuan, liu chuanlei. Clinical significance of detecting blood D-dimer and CEA levels before treatment in colorectal cancer patients. 2024. doi: 10.12201/bmr.202409.00023

  ZHENG Yongfei, ZHOU Minhua, YE Yiping. Study on the regularity of medication of Director Ye Yiping in the treatment of lung cancer based on data mining methods. 2024. doi: 10.12201/bmr.202407.00030

  Guan Wei, Xue Xiaoming. Progress of Trditional Chinese Medicine Targeting Alveolar Epithelial Cell Senescence in the Treatment of Pulmonary Fibrosis. 2025. doi: 10.12201/bmr.202506.00012

  LiYu, Yang Tao, Hu Kongfa. Research on Medication Rules of Famous TCM Physicians in Treating Lung Cancer Based on Hierarchical Community Partition Algorithm. 2021. doi: 10.12201/bmr.202110.00020

  LUAN Zhi-Yong. Research progress of stem cell therapy for Hirschsprung disease. 2024. doi: 10.12201/bmr.202410.00021

• ID	Submit time	Number	Download
  1	2025-05-03	bmr.202506.00015V1	Download

• Public  Anonymous  To author only Submit Comments